Issue Contents
|
Marketing Authorisations
|
|
|
For certain patients at risk of developing severe disease
|
|
|
|
|
|
Effective for at least 3 months, but no proven efficacy against the Omicron variant
|
|
|
|
|
|
|
|
|
Increased incidence of allergic reactions in everyday life
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The complete contents of
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated.
